CORONA Remedies to Host Q4 FY26 Earnings Call on May 12, 2026
CORONA Remedies Limited will hold its Q4 FY26 earnings conference call on May 12, 2026, at 11:00 AM IST. The call will discuss financial results for the quarter and year ended March 31, 2026. Management representatives will include MD & CEO Nirav Mehta and CFO Bhavin Bhagat.
The announcement of an earnings call is important for investors and analysts to understand the company's financial performance and future outlook. It provides a platform for engagement and information dissemination, hence the impact is medium.
The announcement is a routine intimation of a scheduled conference call for discussing financial results, with no specific financial figures or performance indicators provided in the announcement itself. Therefore, the sentiment is neutral.
CORONA Remedies Limited has announced its Q4 FY26 earnings conference call, scheduled for Tuesday, May 12, 2026, at 11:00 a.m. IST. The call will provide a platform to discuss the company's financial results for the fourth quarter and the full fiscal year ended March 31, 2026.
The company representatives who will be present on the call include Mr. Nirav Mehta, Managing Director & CEO, Mr. Ankur Mehta, Joint Managing Director, and Mr. Bhavin Bhagat, Chief Financial Officer. The conference call will be moderated by Gaurav Tinani from Institutional Equities at Ambit Capital.
Participants can join the call via Diamond Pass for a quicker entry. Dial-in details include Primary Access Numbers +91 22 6280 1148 and +91 22 7115 8049, along with international toll-free numbers for Singapore, Hong Kong, USA, and UK. Attendees are requested to join a few minutes prior to the scheduled time.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.